I-MAB completed a workforce reduction as part of a Realignment Plan aimed at optimizing its operations following the pipeline reprioritization. The company reduced its workforce by approximately 27% ...
The approval is based on results from the Phase III FLOW trial demonstrating Ozempic reduced the risk of severe kidney outcomes by 24% compared to placebo, including kidney failure, reduction in ...
miRecule, a biotechnology company developing RNA therapies, and GBI Biomanufacturing, a CDMO, entered a strategic partnership to advance the development and clinical supply of miRecule’s Antibody-RNA ...